- Home
- GXAI vs MYNZ Comparison
GXAI vs MYNZ Comparison
Compare GXAI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- MYNZ
- Stock Information
- Founded
- GXAI 2021
- MYNZ 2021
- Country
- GXAI United States
- MYNZ Germany
- Employees
- GXAI N/A
- MYNZ N/A
- Industry
- GXAI
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- MYNZ Health Care
- Exchange
- GXAI Nasdaq
- MYNZ Nasdaq
- Market Cap
- GXAI 7.3M
- MYNZ 7.0M
- IPO Year
- GXAI 2023
- MYNZ 2021
- Fundamental
- Price
- GXAI $1.32
- MYNZ $2.41
- Analyst Decision
- GXAI
- MYNZ Buy
- Analyst Count
- GXAI 0
- MYNZ 2
- Target Price
- GXAI N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GXAI 100.1K
- MYNZ 303.1K
- Earning Date
- GXAI 05-27-2025
- MYNZ 05-27-2025
- Dividend Yield
- GXAI N/A
- MYNZ N/A
- EPS Growth
- GXAI N/A
- MYNZ N/A
- EPS
- GXAI N/A
- MYNZ N/A
- Revenue
- GXAI $4,027.00
- MYNZ $893,991.00
- Revenue This Year
- GXAI N/A
- MYNZ $42.95
- Revenue Next Year
- GXAI N/A
- MYNZ N/A
- P/E Ratio
- GXAI N/A
- MYNZ N/A
- Revenue Growth
- GXAI 1473.05
- MYNZ N/A
- 52 Week Low
- GXAI $1.00
- MYNZ $0.18
- 52 Week High
- GXAI $7.50
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- GXAI 60.50
- MYNZ 32.38
- Support Level
- GXAI $1.07
- MYNZ $2.18
- Resistance Level
- GXAI $1.44
- MYNZ $2.57
- Average True Range (ATR)
- GXAI 0.08
- MYNZ 0.31
- MACD
- GXAI 0.03
- MYNZ -0.02
- Stochastic Oscillator
- GXAI 67.97
- MYNZ 5.15
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.